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Improved survival in patients obtaining remission of nephrotic
range albuminuria in diabetic nephropathy.
Background. The level of albuminuria is related to progres-
sion of diabetic nephropathy, and patients with nephrotic range
albuminuria have advanced renal structural changes and the
fastest decline in glomerular filtration rate (GFR). We have
previously demonstrated that the rate of decline in GFR is di-
minished in patients obtaining remission of nephrotic range
albuminuria, but information is scarce concerning the impact
of remission of nephrotic range albuminuria on the long-term
prognosis.
Methods. At the Steno Diabetes Center, we performed a
prospective cohort study of all type 1 diabetic patients with
nephrotic range albuminuria (N = 125), who had annual mea-
surement of GFR [51chromium-ethylenediaminetetraacetic
acid (51Cr-EDTA) plasma clearance] carried out for at least
3 years. Patients were followed from onset of nephrotic range
albuminuria until death or the end of year 2003. Nephrotic
range albuminuria was defined as persistent albuminuria above
2.5 g/24 hours, remission of nephrotic range albuminuria was
defined as sustained albuminuria <0.6 g/24 hours for at least
1 year.
Results. Nephrotic range albuminuria occurred in 90 men and
35 women, age [mean (SD)] 34 (8) years, duration of diabetes 22
(8) years, and follow-up time from onset of nephrotic range al-
buminuria [median (range)] 12.4 (3.0 to 24.9) years. Remission
was induced in 32 patients (26%), 25 predominantly treated
with angiotensin-converting enzyme (ACE) inhibitors, seven
with non-ACE inhibitors. The remission lasted 5.5 (1.0 to 22.4)
years. At the end of follow-up, 25% in the remission group and
74% in the no remission group had reached the composite end
point of end-stage renal disease (ESRD) (dialysis, transplanta-
tion) or death. A Cox proportional hazard regression analysis
with gender and age as fixed covariates and remission as time-
dependent covariate revealed that obtaining remission was as-
sociated with a lower risk of dialysis, transplantation, or death,
relative risk (95% CI) 0.28 (0.13 to 0.59), P = 0.001, whereas
older age at onset of nephrotic range albuminuria (per 10-year
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increase) was associated with higher risk of reaching the end
point, 1.42 (1.08 to 1.87), P = 0.01.
Conclusion. Our prospective study suggests that remission
of nephrotic range albuminuria in type 1 diabetic patients, in-
duced by aggressive antihypertensive treatment with and with-
out ACE inhibitors, is associated with a slower progression in
diabetic nephropathy and a substantially improved survival.
Diabetic nephropathy is a chronic progressive kidney
disease with high morbidity and mortality [1], and is char-
acterized by an early elevation of arterial blood pressure,
increasing albuminuria, and a relentless mean decline in
glomerular filtration rate (GFR) of approximately 10 to
12 mL/min/year and extremely high risk of cardiovascu-
lar disease without antihypertensive treatment [2–5]. The
degree of albuminuria is closely related to the progres-
sion of diabetic nephropathy as reviewed by Rossing [6].
The most advanced renal structural changes, the fastest
decline in GFR, the highest risk of cardiovascular dis-
ease, and the shortest survival time are seen in the group
of diabetic patients with diabetic nephropathy and the
highest levels of albuminuria (i.e., nephrotic range albu-
minuria) [7–9]. We have previously demonstrated that
remission of nephrotic range albuminuria, defined as re-
duction of albuminuria from above 2500 mg per 24 hours
to below 600 mg per 24 hours, is associated with a slower
deterioration of kidney function [10]. However, whether
remission of nephrotic range albuminuria will transfer
in to a better long-term prognosis and survival remains
to be elucidated. To evaluate the impact of remission of
nephrotic range albuminuria on the composite end point:
end-stage renal disease (ESRD) (dialysis or transplan-
tation) or death, we analyzed data from our long-term
prospective observational study of 125 consecutive type
1 diabetic patients with nephrotic range albuminuria due
to diabetes.
METHODS
The patients with nephrotic range albuminuria have
been described in detail previously [10]. In brief, we
evaluated all type 1 diabetic patients with diabetic
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nephropathy at the Steno Diabetes Center, who had their
kidney function monitored with at least one yearly de-
termination of GFR and a minimum of 3 years follow-up
(N = 321). Of the total cohort (200 men), nephrotic range
albuminuria developed in 125 patients (90 men) [10]. In
the present study, the follow-up was extended to the end
of the year 2003. Diabetic nephropathy was diagnosed
clinically if the following criteria were fulfilled: persis-
tent albuminuria > 300 mg/24 hours in at least two out of
three consecutive 24-hour urine collections, presence of
diabetic retinopathy, and absence of any other evidence
of kidney or renal tract disease [11]. As previously re-
ported, nephrotic range albuminuria was defined as per-
sisting albuminuria above 2500 mg/24 hours in at least
two out of three consecutive 24-hour urine collections,
and remission was accordingly defined as a reduction in
albuminuria from nephrotic range albuminuria to below
600 mg/24 hours, sustained for at least 1 year during the
follow-up period [10]. ESRD was defined as commence-
ment of renal replacement therapy. All definitions were
pre specified prior to data analysis.
At onset of nephrotic range albuminuria (baseline),
67 patients (54%) were without antihypertensive treat-
ment, 24 (19%) treated predominately with angiotensin-
converting enzyme (ACE) inhibitors and 34 (27%)
patients were treated with other antihypertensive agents
than ACE inhibitors [10]. During follow-up, all 125 pa-
tients except one started antihypertensive treatment, 103
(82%) patients predominately with ACE inhibitors, and
21 (17%) with other antihypertensive agents. Patients
were classified as taking ACE inhibitors if this class of
antihypertensive agents were prescribed before or during
the individual follow-up time. During the entire follow-
up period, we strived to keep blood pressure below
140/90 mm Hg. Fourteen percent of the patients received
monotherapy, 44% received two agents, 35% received
three agents, and 7% were treated with four or more an-
tihypertensive drugs.
All patients took at least two daily injections of insulin
and had a diabetic diet containing 45% to 55% carbo-
hydrates, 30% to 35% fat, and 15% to 20% protein. No
sodium or protein restrictions were applied during the
study. Lipid-lowering treatment and aspirin were used
as secondary prevention in patients with concomitantly
cardiovascular disease.
Procedures
GFR was measured after a single intravenous injec-
tion of 3.7 mBq 51chromium-ethylenediaminetetraacetic
acid (51Cr-EDTA) by determination of the radioactiv-
ity in venous blood samples taken 180, 200, 220, and
240 minutes after the injection [12]. The mean variability
in GFR of each patient from day to day was 4%. Results
are standardized to 1.73 m2 body surface. Number of GFR
measurements ranged from 3 to 41 (median 12) in each
patient, and follow-up from 3 to 24.9 years (median 12.4)
[10]. All patients visited the outpatient clinic every 3 to
4 months during the study. Blood glucose concentration,
glycosylated hemoglobin A1c (Hb1c), albuminuria, blood
pressure, and body weight was monitored, and the insulin
dose and antihypertensive treatment were adjusted.
Albuminuria was measured in 24-hour urine collec-
tions as well as in timed urine collections, obtained during
the 4-hour clearance period [10]. Glycosylated HbA1c
was measured from venous blood samples by isoelec-
tric focusing and high-performance liquid chromatogra-
phy (HPLC) [10]. The normal range was 4.1% to 6.4%.
Serum cholesterol was measured with standard labora-
tory techniques. Arterial blood pressure was measured at
each visit with a standard mercury sphygmomanometer
and appropriate cuff size. The measurements were per-
formed twice, on the right arm, after at least 10 minutes
rest and averaged. Diastolic blood pressure was recorded
at the disappearance of Korotkoff sounds (phase V). Ar-
terial hypertension was diagnosed according to the World
Health Organization (WHO) criteria (≥160/95 mm Hg)
until 1995 and thereafter according to the American
Diabetes Association criteria (≥140/90 mm Hg) [13].
Retinopathy was assessed after pupillary dilatation by
ophthalmoscopy. From 1991, evaluation was performed
by fundus photography and graded nil, simplex, or pro-
liferative diabetic retinopathy.
Date of death was recorded, and information on the
cause of death obtained from death certificates. Follow-
up ended December 31, 2003. All death certificates were
reviewed independently by two observers and the pri-
mary cause of death recorded. If patients had entered re-
nal replacement therapy, the cause of death was coded
as ESRD independently of the causes given on the
death certificate. Available additional information from
necropsy reports was included.
Statistical analysis
Results are expressed as means and standard deviation
(SD) for descriptive information. Albuminuria is given
as median (range) and was logarithmically transformed
before analysis. Linear regression analysis, least squares
method, was used to determine the slope of GFR for each
patient. Two Cox proportional hazards regression analy-
ses were performed: one with the combined end point of
ESRD or death as end point, the other with death only as
end point. A proportional hazards model with time since
nephrotic range albuminuria as timescale was used. Fixed
covariates in the analyses were gender, and age at onset of
nephrotic range albuminuria. A model with glycosylated
HbA1c included as fixed covariate was also performed
in the patients where this parameter was measured at
baseline. Remission of nephrotic range albuminuria was
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Table 1. Baseline data in 125 type 1 diabetic patients with diabetic
nephropathy at onset of nephrotic range albuminuria




Heighta cm 173 ± 8
Age at onset of nephrotic range 34 ± 8
albuminuriaa years
Age at onset of diabetesa years 12 ± 8
Retinopathy simplex/proliferative 28/97
Smoking yes/no 68/57
Glomerular filtration ratea 78 ± 24
mL/min/1.73 m2
Systolic blood pressurea mm Hg 145 ± 15
Diastolic blood pressurea mm Hg 89 ± 8
Mean arterial blood pressurea mm Hg 108 ± 9
Albuminuriab mg/24 hours 2647 (515–7448)
Glycosylated hemoglobin A1ca % 9.3 ± 1.4
Serum cholesterola mmol/L 6.4 ± 1.5
Mean of values during the first year after onset of nephrotic range albuminuria
are given. Consequently, some patients with previously persistent nephrotic range
albuminuria receiving antihypertensive treatment had baseline albuminuria
below 2500 mg/24 hours.
aMean ± SD; bMedian (range).
entered as time-dependent covariate with value 0 up to
the time of remission, and after that a value of 1. Delayed
entry was used due to the inclusion criterion of annual
GFR measurement for at least 3 years. Cox proportional
hazards regression analysis was performed by the freely
available software R (http://www.ci.tuwien.ac.at/R).
RESULTS
We analyzed data from 125 patients (90 men and
35 women) with a median follow-up time of 12.4 (3.0
to 24.9) years from onset of nephrotic range albumin-
uria. Baseline data for all 125 patients are shown in
Table 1. Clinical and laboratory data at baseline are cal-
culated as mean of values during the first year after onset
of nephrotic range albuminuria. Risk factors for cardio-
vascular disease at baseline, grouped by patients subse-
quently obtaining or not obtaining remission of nephrotic
range albuminuria, are shown in Table 2.
Clinical and laboratory data during follow-up are pre-
sented in details elsewhere [10]. Arterial blood pressure
and serum cholesterol was lower in the patients obtain-
ing remission, while no difference was demonstrated in
glycemic control during follow up, measured as HbA1c,
between groups. Per definition, albuminuria was signifi-
cantly lower in the remission group. The present analysis
confirms previous findings, as patients obtaining remis-
sion had a significantly lower rate of decline in GFR dur-
ing the entire follow-up period as compared to patients
not obtaining remission (3.2 mL/min/year vs. 7.4 mL/
min/year, P < 0.001).
Remission was induced in 32 patients (26%), and lasted
5.5 (1.0 to 22.4) years. Of these 32 patients, 25 patients
Table 2. Baseline data and treatment during follow-up in 125 type 1
diabetic patients with diabetic nephropathy and nephrotic range





(N = 32) (N = 93) P value
Baseline data
Gender male/female 18/14 72/21† <0.05
Body mass indexa kg/m2 24.4 ± 2.8 23.7 ± 3.1 NS
Age at onset of nephrotic range 33 ± 7 35 ± 9 NS
albuminuriaa years
Smoking yes/no 15/17 53/40 NS
History of ischemic heart 0/32 6/87 NS
disease yes/no
History of stroke yes/no 0/32 5/88 NS
Glomerular filtration ratea 81 ± 25 78 ± 23 NS
mL/min/1.73 m2
Systolic blood pressurea mm Hg 144 ± 12 146 ± 16 NS
Diastolic blood pressurea mm Hg 90 ± 8 89 ± 8 NS
Albuminuriab mg/24 hours 2577 2677 NS
(515–4800) (893–7448)
Glycosylated hemoglobin A1ca % 9.0 ± 1.6 9.4 ± 1.3 NS
Serum cholesterola mmol/L 6.4 ± 1.8 6.3 ± 1.3 NS
Treatment during follow-up
Mean number of antihypertensive 2.5 2.3 NS
agentsa
Antihypertensive treatment 0/7/25 1/14/78 NS
(nil/non-ACEinhibitors/
ACE inhibitors)
Diuretics yes/no 26/32 71/22 NS
Lipid-lowering treatment yes/no 6/26 17/76 NS
Total follow-up timeb years 14.6 11.2 <0.05
(7.2–24.9) (3.0–24.9)
ACE is angiotensin-converting enzyme. Baseline values are mean of values
during the first year after onset of nephrotic range albuminuria. Consequently,
some patients with previously persistent nephrotic range albuminuria receiving
antihypertensive treatment had baseline albuminuria below 2500 mg/24 hours.
aMean ± SD; bMedian (range).
were treated with ACE inhibitors, and seven patients with
non-ACE inhibitors. The occurrence of remission was
24% (95% CI 16 to 32) in all patients treated with ACE
inhibitors versus 33% (95% CI 13 to 53) in the non-ACE
inhibitor–treated patients, NS. There was no difference
in the use of diuretics (81% in the remission group versus
76% in the no remission group, NS). During follow-up,
similar numbers of antihypertensive agents was used in
patients obtaining or not obtaining remission, NS. The
proportion of patients treated with lipid-lowering drugs,
predominately statins, was 19% in the remission group
and 18% in the no remission group, NS.
During the 12.4 years of follow-up, four patients pro-
gressed to ESRD and four died in the remission group
(25% of the patients in the remission group reached the
composite end point), whereas 31 patients progressed to
ESRD and 38 died in the no remission group (74% of the
patients in the no remission group reached the compos-
ite end point). In the remission group, one patient died
after initiation of renal replacement therapy, resulting in
a total of five deceased patients in this group (two due to
Hovind et al: Remission of nephrotic range albuminuria 1183
Table 3. Cox proportional hazard regression analysis of the impact of
remission of nephrotic range albuminuria on the composite end point
of end-stage renal disease (ESRD) or death in 125 type 1 diabetic
patients with diabetic nephropathy
Remission
Total Yes No
Number of patients 125 32 93
Number of events 77 8 69
Follow-up time years 8.7 8.1 8.9
Cox model
Outcome ESRD or death
Time scale Time since nephrotic range albuminuria
Entry 2.5 years after nephrotic range albuminuria
Estimates Relative risk (95% CI) P value
Fixed covariates
Gender (female vs. male) 0.92 (0.53 to 1.57) 0.740
Age at entry (per 10 years) 1.42 (1.08 to 1.87) 0.011
Time-dependent covariate
Obtained remission 0.28 (0.13 to 0.59) 0.001
Table 4. Cox proportional hazard regression analysis of the impact of
remission of nephrotic range albuminuria on mortality in 125 type 1
diabetic patients with diabetic nephropathy
Remission
Total Yes No
Number of patients 125 32 93
Number of events 50 5 45
Follow-up time years 10.2 8.3 10.8
Cox model
Outcome Death
Time scale Time since nephrotic range albuminuria
Entry 2.5 years after nephrotic range albuminuria
Estimates Relative risk (95% CI) P value
Fixed covariates
Gender (female vs. male) 0.93 (0.48 to 1.80) 0.830
Age at entry (per 10 years) 1.60 (1.14 to 2.23) 0.006
Time-dependent covariate
Obtained remission 0.37 (0.14 to 0.94) 0.036
cardiovascular disease, two died of infections, while one
died of unknown cause). In the no remission group, seven
patients died after commencement of renal replacement
therapy. The main cause of death was cardiovascular
disease, accounting for 64% of deaths in this group.
Twenty-five patients died from acute myocardial infarc-
tion or ischemic heart disease and four died of cere-
brovascular disease.
The estimates of the Cox proportional hazard regres-
sion analysis for both the combined end point of death
and ESRD, and for death alone are given in Tables 3 and
4. The effect of gender is nonsignificant, but does not ex-
clude substantial differences between the genders. Age
has a substantial effect, as rates increases about 50% per
10 years. The effect of remission of nephrotic range al-
buminuria is strong, with a reduction of both ESRD and
mortality by some 60%. The confidence limits are such
that the minimally tenable reduction is 40% (upper 95%
confidence limit for relative risk is 0.59).
Glycosylated HbA1c at baseline was only determined
in a subset of the patients (97 of the 125 patients), since
this method was not available in the remaining patients at
baseline examnation. A sub-analysis, including glycosy-
lated HbA1c as fixed covariate, was performed (Table 5).
The effect of glycosylated HbA1c on the combined end
point as well as death only is statistically significant. The
estimated effect of remission is essentially unaffected af-
ter glycosylated HbA1c inclusion in analysis as compared
with analysis performed in all 125 patients without glyco-
sylated HbA1c. However the reduced number of patients
in this sub analysis makes the confidence limits wider
(Table 5).
DISCUSSION
Our prospective observational study demonstrates
long lasting remission of nephrotic range albuminuria,
obtained by aggressive antihypertensive therapy with and
without ACE inhibitors, is associated with a significantly
slower progression of diabetic nephropathy, and a sub-
stantially reduction in patients progressing to ESRD or
death during the 12 years of follow-up.
Originally, Watkins et al [7] performed a follow-up
study in proteinuric type 1 diabetic patients and reported
that patients with proteinuria above 3000 mg per 24 hours
all died after 2 to 6 years of follow-up, thus identifying a
subset of patients with a very poor prognosis. In a ret-
rospective study, Kussman, Goldstein, and Gleason [9]
demonstrated diabetic kidney disease to be a chronic,
progressive and irreversible disease with an accelerated
loss in kidney function in the later stages of the disease.
Furthermore, it has been demonstrated that patients with
nephrotic range albuminuria have the fastest decline in
GFR and more advanced structural changes as compared
to patients with non-nephrotic range albuminuria [8]. In
an observational study of 301 type 1 diabetic patients,
we have previously demonstrated that patients with the
highest levels of albuminuria have the fastest decline in
GFR [14]. Thus, a subset of diabetic patients with diabetic
nephropathy with a particular poor prognosis can be iden-
tified by the level of albuminuria. Long-term remission of
nephrotic range proteinuria was originally demonstrated
by Wilmer et al [15], where antihypertensive treatment
induced remission in a small subset (6 of 103 patients)
of type 1 diabetic patients with diabetic nephropathy and
nephrotic range proteinuria. We confirmed and extended
these findings by demonstrating that patients obtaining
remission of nephrotic range albuminuria have a signifi-
cantly lower decline in GFR as compared to patients not
obtaining remission.
Albuminuria is a clinical marker of kidney damage, and
reduction in albuminuria is used as a surrogate parame-
ter for renoprotection in clinical trials, with the excep-
tion of remission of massive proteinuria (i.e., nephrotic
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Table 5. Cox proportional hazard model, including glycosylated hemoglobin A1c in the subanalysis of the impact of remission of nephrotic range
albuminuria on death or end-stage renal disease (ESRD), or mortality alone, in 97 type 1 diabetic patients with diabetic nephropathy
ESRD or death Death alone
Cox model
Outcome ESRD or death Death
Time scale Time since nephrotic range albuminuria Time since nephrotic range albuminuria
Entry 2.5 years after nephrotic range albuminuria 2.5 years after nephrotic range albuminuria
Estimates Relative risk (95% CI) P value Relative risk (95% CI) P value
Fixed covariates
Gender (female vs. male) 0.72 (0.36 to 1.46) 0.370 0.89 (0.38 to 2.09) 0.790
Age at entry (per 10 years) 1.34 (0.99 to 1.82) 0.061 1.50 (1.02 to 2.20) 0.039
Glycosylated hemoglobin A1c 1.32 (1.11 to 1.57) 0.002 1.40 (1.13 to 1.72) 0.002
Time-dependent covariate
Obtained remission 0.28 (0.10 to 0.78) 0.016 0.40 (0.12 to 1.33) 0.130
syndrome), which may be used as a principal end point
[16]. Development of persistent proteinuria is a major
life-threatening complication in patients with type 1 dia-
betes [17], and in that perspective even the rate of decline
in GFR may be regarded as a surrogate end point as op-
posed to ESRD and mortality. In the RENAAL Study in
type 2 diabetes, the baseline levels as well as the initial
reduction in proteinuria has been demonstrated to be a
strong predictor of ESRD and cardiovascular morbidity
[18]. Every 50% reduction in proteinuria within the first
6 months halved the risk for cardiovascular end points
and heart failure during follow-up [18]. However, no stud-
ies in type 1 diabetic patients have so far evaluated the
impact of remission of nephrotic range albuminuria on
the hard end points, ESRD and mortality. In the present
study, we demonstrate for the first time that remission
from nephrotic range albuminuria is associated with a
reduction in patients progressing to ESRD, and a sub-
stantially improved survival in type 1 diabetic patients
with diabetic nephropathy.
In a prospective observational study including 939 type
1 diabetic patients followed for 10 years, glycemic control
was found to be an independent predictor of all-cause
mortality with a relative risk of 1.11 (95% CI 1.03 to
1.20) [19]. Our study confirm and extend this observa-
tion, as glycemic control was found to be associated with
the combined end point of death or ESRD as well as
mortality alone in the subset of patients with the poor-
est prognosis (i.e., patients with nephrotic range albu-
minuria). Development of overt diabetic nephropathy
has for many years been regarded as “a point of no re-
turn” in relation to glycemic control and progression of
diabetic kidney disease. However, successful pancreatic
transplantation resulting in normoglycemia for 10 years
induced reversal of established diabetic glomerular le-
sions in type 1 diabetic patients. In summary, to improve
the prognosis in patients with diabetic nephropathy the
available data suggest that improved glycemic control is
of importance, and implies vigorous efforts to normalize
hyperglycemia.
In epidemiologic studies dealing with the natural his-
tory of diabetic nephropathy, the median survival time
after onset of persistent proteinuria has been reported to
be from 5 to 10 years [22–24]. After aggressive antihyper-
tensive treatment has been introduced in patients with
diabetic nephropathy, the median survival time now ex-
ceeds 16 years in these patients [25]. Although the relative
cardiovascular mortality in proteinuric type 1 diabetic pa-
tients is 37-fold that in the general population [5], uremia
has been the main cause of death in the earlier studies
performed before [22–24] as well as after [25] the use of
antihypertensive treatment was generally established in
patients with diabetic nephropathy. In the subset of pa-
tients with nephrotic range albuminuria, well known to
have a high risk of progressing to ESRD, we report that
even though uremia still is the main cause of progressing
to the composite end point, cardiovascular disease has be-
come increasingly more prevalent. Thus, suggesting that
the improved kidney prognosis reveals a new great chal-
lenge in these patients: prevention, early detection, and
treatment of cardiovascular disease.
In the present study, approximately one out five pa-
tient obtained remission, and may be therefore be re-
garded as responders. Identifying factors with impact on
a beneficial response is not only of academic interest,
since identification of such factors would have huge im-
pact on the treatment and prognosis in patients. Classical
and established risk factors for progression of diabetic
kidney disease (i.e., arterial blood pressure, albuminuria,
HbA1c, and lipids), measured at onset of nephrotic range
albuminuria were similar at onset of nephrotic range al-
buminuria in responders and nonresponders [10], thus
other determinants of remission must be taken in to con-
sideration. As previously discussed, variation in dietary
salt intake and activity of the renin-angiotensin system
could contribute to the difference between responders
and nonresponders [10]. Furthermore, in observational
studies such as ours the compliance concerning adher-
ence to prolonged antihypertensive treatment are not as-
sessed directly, although the number of antihypertensive
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agents prescribed in responders and nonresponders was
similar in our study. Patient compliance with drug ther-
apy has been recognized as one of the major reasons why
antihypertensive therapy fails in the United States and
elsewhere [26], and subsequently noncompliers may be
misclassified as nonresponders. The use of several anti-
hypertensive agents in order to control blood pressure
may reduce compliance even further. Poor adherence to
antihypertensive treatment can be observed in patients
with uncontrolled hypertension as well as in well con-
trolled blood pressure [27], which may imply that even
at the same blood pressure level, nonadherence to ACE
inhibitor therapy will render the patients without the non-
hemodynamic beneficial effects of these compounds [28,
29].
Although many non genetic factors may influence the
effects of medications, there is now growing evidence for
genetic factors being responsible for individual response
to therapy. Exner et al [30] demonstrated differences in
response to ACE inhibitor treatment between black and
white patients with left ventricular dysfunction. However,
racial categorization is only a surrogate marker for differ-
ent inherited determinants of drug response. There are
now examples of cases in which interindividual differ-
ences in drug response are due to sequence variants in
genes encoding drug-metabolizing enzymes, drug trans-
porters, or drug targets as reviewed by Evans and McLeod
[31]. It is estimated that genetics can account for 20% to
95% of variability in drug deposition and effects [32]. Un-
fortunately, DNA for genotyping was only available in a
subset of the investigated patients. However in the future,
genetic factors of importance for the progression of di-
abetic nephropathy could possibly differentiate between
the responders and nonresponders.
CONCLUSION
Our prospective study demonstrates that remission of
nephrotic range albuminuria, induced by antihyperten-
sive treatment with and without ACE inhibitors, is asso-
ciated with a slower progression in diabetic nephropathy
and a substantially improved survival in type 1 diabetic
patients with diabetic nephropathy. The improved kidney
prognosis with longer survival free of ESRD reveals the
urgent need for targeting early prevention, detection, and
treatment of cardiovascular disease. The beneficial results
observed in our study were obtained despite the fact that
only a minority of patients received statins and low dose
aspirin, and more than 50% were smokers. At present
time, we at the Steno Diabetes Center have changed the
treatment strategy to include statins and low dose aspirin
in all our patients with albuminuria. Furthermore, an ag-
gressive approach toward smoking cessation has been in-
troduced.
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